This page is intended to provide scientific information to scientific research professionals. Gossamer Bio’s drug candidates are investigational medicines and have not been approved by The United States Food and Drug Administration (USFDA), Health Canada, the European Medicines Agency (EMA), nor any other regulatory agency.
A Phase 1B, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects With WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Phase 2 Clinical Study to Evaluate the Efficacy and Safety of Inhaled GB002 for the Treatment of World Health Organization Group 1 Pulmonary Arterial Hypertension
GB004 Exhibits Protective Effects Directly on Epithelial Cells Using Ex Vivo Organoid and Monolayer Cultures
GB004 Phase 1b Data Presentation at UEGW Virtual 2020
Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36)
Combining Transcriptomic- and Tissue-Based Immune Biomarkers to Evaluate GB1275, a CD11b Modulator, as a Single Agent or With Pembrolizumab in Patients With Advanced Solid Tumors